UBS analyst Colin Bristow downgraded Applied Therapeutics (APLT) to Neutral from Buy with a price target of $2, down from $13.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on APLT:
- Applied Therapeutics price target lowered to $5 from $14 at Baird
- Applied Therapeutics (APLT) Stock Plunges 75% as FDA Rules Against Genetic Drug
- Applied Therapeutics target lowered to $8, ‘catalyst watch’ removed at Citi
- Unusually active option classes on open November 29th
- Voyager upgraded, HP downgraded: Wall Street’s top analyst calls